The Valley Desk

NCT02229396 · Interventional trial

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Overall registry status Completed

Phase 3

Conditions Diabetes Mellitus

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov